TEVOGEN BIO HOLDINGS INC (NASDAQ: TVGN)

TEVOGEN BIO HOLDINGS INC

NASDAQ: TVGN (Tevogen Bio Holdings Inc.)

最近更新时间: 4天之前, 6:02AM

1.20

0.00 (0.00%)

加入群组

前收盘价格	1.20
收盘价格	1.22
成交量	217,346
平均成交量 (3个月)	2,097,001
市值	210,061,216

市盈率 (P/E TTM)

3.43

52周波幅

0.256 (-78%) — 4.78 (298%)

市场趋势

		短期	中期
行业	Biotechnology (US)	混合的	混合的
	Biotechnology (全球的)	混合的	混合的
股票	Tevogen Bio Holdings Inc.	-	-

AIStockmoo 评分

-1.4

分析师共识	0.5
内部交易活动	NA
价格波动	-2.0
技术平均移动指标	0.0
技术振荡指标	-4.0
平均	-1.38

相关股票

股票	市值	DY	P/E（TTM）	P/B
TVGN	210 M	-	3.43	-
LEGN	6 B	-	-	6.69
MTSR	2 B	-	-	-
CNTA	2 B	-	-	4.84
GYRE	686 M	-	146.50	13.47
UPB	338 M	-	-	0.740

Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes (“CD8+ CTLs” or “CTLs”), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders.
部门	Healthcare
行业	Biotechnology
内部持股比例	91.35%
机构持股比例	1.47%

所有权

姓名	日期	持有股份
China Universal Asset Management Co., Ltd.	31 Dec 2024	37,117

52周波幅	0.256 (-78%) — 4.78 (298%)
中	10.00 (733.33%)
总计	1 购买

公司	日期	目标价格	调整类型	价格@调整类型
D. Boral Capital	11 Mar 2025	10.00 (733.33%)	购买	1.07
D. Boral Capital	04 Mar 2025	10.00 (733.33%)	购买	1.27

该时间范围内无数据。

日期	类型	细节
26 Mar 2025	公告	Tevogen Bio CEO Named to NJBIZ 2025 Health Care Power List as Company Advances Commercialization; Reaffirms Timeframe on Previously Announced Forecast
25 Mar 2025	公告	Tevogen Bio Appoints David E. Banko as Global Head of Government Affairs and Patient Access, Advances Commercialization Plan
10 Mar 2025	公告	Tevogen Bio Announces Unique T Cell Vaccine Under Development and Files Patent with the USPTO
07 Mar 2025	公告	Tevogen Bio’s CIO & Head of Tevogen.AI, Mittul Mehta, Featured Speaker at Proskauer’s AI Discussion Panel
03 Mar 2025	公告	Tevogen Bio to Receive $8 Million of Non-Dilutive Grant Funding, Reiterates Efficient Operations
28 Feb 2025	公告	Tevogen Bio Founder and CEO Dr. Ryan Saadi Named to 2025 NJBIZ Power 100, Celebrating Innovation and Leadership in Accessible T Cell Therapy
21 Feb 2025	公告	Tevogen Bio’s First Trading Year Efficiency: 600% Higher Market Cap Per Team Member, 79% Insider-Owned
14 Feb 2025	公告	Tevogen Bio CEO Reinforces Commitment to Retention of Equity Capital and Long-Term Vision
14 Feb 2025	公告	Tevogen Bio CEO Addresses Short Selling and Its Potential Impact on the Nation’s Health and Prosperity
14 Feb 2025	公告	Tevogen Bio Shares 2024 Financing Activity on One Year Anniversary of Becoming a Publicly Listed Company; Highlights Operational Efficiency
13 Feb 2025	公告	Tevogen Bio CEO Congratulates RFK Jr. on His Confirmation as Secretary of the HHS; Echoes Commitment to Innovation and Affordability for Americans
10 Feb 2025	公告	Tevogen Bio's Business Model Addresses Biopharma Industry Challenges with Cost-Efficient Innovation
07 Feb 2025	公告	Tevogen Bio Meets BARDA TechWatch Team, Highlighting ExacTcell™ Technology’s Potential as a Scalable Medical Countermeasure
28 Jan 2025	公告	Tevogen Bio Enters Agreement to Receive Up To $10 Million of Non-Dilutive Grant Funding
27 Jan 2025	公告	Tevogen Bio CEO Congratulates Lynne Patton on Being Appointed Deputy Assistant to the President and Director of Minority Outreach
24 Jan 2025	公告	Tevogen Bio Broadens Relationship with Microsoft to Deepen Artificial Intelligence Collaboration and Develop PredicTcell Technology on Azure
23 Jan 2025	公告	Tevogen Bio Highlights the Future of AI-Driven Drug Development in Fireside Chat with Microsoft During the J.P. Morgan Healthcare Conference
显示更多

支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。

投资组合

请登录以添加到您的群组

AI 建议策略模板

自定义的价格提醒

开始购买价格 (EP)

第一个目标价格赚取利润 (TP1)

第二个目标价格赚取利润 (TP2)

停止损失价格 (SL)

请登录以添加到您的群组

已实现利润	-
未实现利润	-
收到股息 2025	-
利润总额	-
平均回报	-
数量(购买)	-
平均价格(购买)	-
数量(卖出)	-
平均价格(卖出)	-

请登录以添加到您的群组

没有符合您标准的股票

流动比率 (MRQ)	0.340
营业现金流 (OCF TTM)	-10.93 M
杠杆自由现金流 (LFCF TTM)	8.62 M

安全边际 (EP)
部分利润 (TP1)
目标利润 (TP2)
最大损失 (SL)